245 related articles for article (PubMed ID: 9439509)
1. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
Davies SW; Beardsall K; Turmaine M; DiFiglia M; Aronin N; Bates GP
Lancet; 1998 Jan; 351(9096):131-3. PubMed ID: 9439509
[TBL] [Abstract][Full Text] [Related]
2. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset.
Gourfinkel-An I; Cancel G; Duyckaerts C; Faucheux B; Hauw JJ; Trottier Y; Brice A; Agid Y; Hirsch EC
Neuroreport; 1998 Jun; 9(8):1823-6. PubMed ID: 9665608
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
4. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
[TBL] [Abstract][Full Text] [Related]
5. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
Davies SW; Turmaine M; Cozens BA; DiFiglia M; Sharp AH; Ross CA; Scherzinger E; Wanker EE; Mangiarini L; Bates GP
Cell; 1997 Aug; 90(3):537-48. PubMed ID: 9267033
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
[TBL] [Abstract][Full Text] [Related]
7. Transgenic models of Huntington's disease.
Sathasivam K; Hobbs C; Mangiarini L; Mahal A; Turmaine M; Doherty P; Davies SW; Bates GP
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):963-9. PubMed ID: 10434294
[TBL] [Abstract][Full Text] [Related]
8. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
[TBL] [Abstract][Full Text] [Related]
9. Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.
Lunkes A; Trottier Y; Fagart J; Schultz P; Zeder-Lutz G; Moras D; Mandel JL
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1013-9. PubMed ID: 10434300
[TBL] [Abstract][Full Text] [Related]
10. Polyglutamines, nuclear inclusions and neurodegeneration.
Lunkes A; Mandel JL
Nat Med; 1997 Nov; 3(11):1201-2. PubMed ID: 9359692
[No Abstract] [Full Text] [Related]
11. Polyglutamine pathogenesis.
Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
[TBL] [Abstract][Full Text] [Related]
12. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.
Sieradzan KA; Mechan AO; Jones L; Wanker EE; Nukina N; Mann DM
Exp Neurol; 1999 Mar; 156(1):92-9. PubMed ID: 10192780
[TBL] [Abstract][Full Text] [Related]
13. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
Ross CA
Neuron; 1997 Dec; 19(6):1147-50. PubMed ID: 9427237
[No Abstract] [Full Text] [Related]
14. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
15. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain.
Díaz-Hernández M; Moreno-Herrero F; Gómez-Ramos P; Morán MA; Ferrer I; Baró AM; Avila J; Hernández F; Lucas JJ
J Neurosci; 2004 Oct; 24(42):9361-71. PubMed ID: 15496672
[TBL] [Abstract][Full Text] [Related]
16. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.
Schilling G; Becher MW; Sharp AH; Jinnah HA; Duan K; Kotzuk JA; Slunt HH; Ratovitski T; Cooper JK; Jenkins NA; Copeland NG; Price DL; Ross CA; Borchelt DR
Hum Mol Genet; 1999 Mar; 8(3):397-407. PubMed ID: 9949199
[TBL] [Abstract][Full Text] [Related]
17. Formation of polyglutamine inclusions in non-CNS tissue.
Sathasivam K; Hobbs C; Turmaine M; Mangiarini L; Mahal A; Bertaux F; Wanker EE; Doherty P; Davies SW; Bates GP
Hum Mol Genet; 1999 May; 8(5):813-22. PubMed ID: 10196370
[TBL] [Abstract][Full Text] [Related]
18. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
20. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
